Laith Alomari, MD1, Zaid Al-Fakhouri, MD2, Tinsae Anebo, MD3, Daniel M. Simadibrata, MD2, Emmanuel Otabor, MBBS1, Justin Lam, MD1, Ahmad Abdulraheem, MD4, Thai Hau Koo, MD5, Ahmed A. Abdulelah, MD6, Jana Alomari, MS7, Chidera Onwuzo, MBBS8 1Thomas Jefferson University, Philadelphia, PA; 2Case Western Reserve University / MetroHealth, Cleveland, OH; 3Jefferson Einstein Hospital/Thomas Jefferson University, Philadelphia, PA; 4MedStar Washington Hospital Center, Washington, DC; 5University of Sciences Malaysia Specialist Hospital, Kelantan, Kelantan, Malaysia; 6Royal Papworth Hospital, Cambridge, England, United Kingdom; 7Jordan University of Science and Technology, Irbid, Irbid, Jordan; 8SUNY Upstate Medical University Hospital, Syracuse, NY Introduction: Barrett’s esophagus (BE) is a known precursor to esophageal adenocarcinoma. While the chemopreventive role of statins has been previously suggested, real-world data from large, nationally representative populations remain limited. Furthermore, the impact of statins on the need for endoscopic interventions—such as radiofrequency ablation and endoscopic mucosal resection—has not been well studied Methods: We conducted a retrospective, population-based cohort study using the TriNetX US Collaborative Network, which includes data from 67 healthcare organizations. Adults with BE were divided into two cohorts based on statin exposure: those with consistent statin use for at least 6 months and those without any statin exposure. Propensity score matching (1:1) was used to balance cohorts on demographics (age, sex, race, ethnicity), comorbidities (including cardiovascular disease, gastroesophageal reflux, and tobacco use), BMI, and concurrent medication use (including aspirin and NSAIDs). The primary outcomes were the need for endoscopic intervention and the incidence of esophageal cancer. Secondary outcome included all-cause mortality. Analyses included hazard ratios, Kaplan-Meier survival, and risk estimates over a 5-year follow-up Results: Statin use was associated with lower risk of endoscopic intervention (HR 0.66; 95% CI: 0.59–0.72; p < 0.001) and esophageal cancer (HR 0.60; 95% CI: 0.53–0.70; p < 0.001). All-cause mortality was also lower among statin users (HR 0.57; 95% CI: 0.54–0.60; p < 0.001). Kaplan-Meier analysis confirmed significantly improved survival in statin users for all outcomes. Discussion: In this large real-world analysis, consistent statin use in patients with Barrett’s esophagus was associated with significantly reduced risks of esophageal cancer, endoscopic therapy, and overall mortality. These findings highlight the value of statins as a potential chemopreventive agent and demonstrate the utility of population-level data in supporting real-world treatment decisions.
Disclosures: Laith Alomari indicated no relevant financial relationships. Zaid Al-Fakhouri indicated no relevant financial relationships. Tinsae Anebo indicated no relevant financial relationships. Daniel Simadibrata indicated no relevant financial relationships. Emmanuel Otabor indicated no relevant financial relationships. Justin Lam indicated no relevant financial relationships. Ahmad Abdulraheem indicated no relevant financial relationships. Thai Hau Koo indicated no relevant financial relationships. Ahmed Abdulelah indicated no relevant financial relationships. Jana Alomari indicated no relevant financial relationships. Chidera Onwuzo indicated no relevant financial relationships.
Laith Alomari, MD1, Zaid Al-Fakhouri, MD2, Tinsae Anebo, MD3, Daniel M. Simadibrata, MD2, Emmanuel Otabor, MBBS1, Justin Lam, MD1, Ahmad Abdulraheem, MD4, Thai Hau Koo, MD5, Ahmed A. Abdulelah, MD6, Jana Alomari, MS7, Chidera Onwuzo, MBBS8. P4913 - Statin Use in Patients With Barrett’s Esophagus Is Associated With Reduced Need for Endoscopic Intervention: A Population-Based Study, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
